Skip to main content

Table 2 IDC molecular subtype analysis relative to FRA staining – TMA data

From: Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease

Variable FRA positive FRA negative Total P valuea
  N (%) N (%)   
Marker     
  ER/PR(+) 4 (14%) 24 (86%) 28  
  ER/PR(-) 14 (45%) 17 (55%) 31 0.012
  Her2(+) 2 (15%) 11 (85%) 13  
  Her2(-) 16 (35%) 30 (65%) 46 0.307
  ER/PR/Her2(-) 12 (67%) 6 (33%) 18 <0.0001
     [ER/PR(+) or Her2(+) vs ER/PR/Her2(-)]
TNM Classification     
  T1 3 (43%) 4 (57%) 7  
  T2 10 (26%) 29 (74%) 39  
  T3 5 (63%) 3 (37%) 8  
  T4 0 (0%) 5 (100%) 5  
Nodal Status     
  N0 18 (35%) 33 (65%) 51  
  N1/N2b 0 (0%) 8 (100%) 8 0.092
Tumor Grade     
  Grade 1 1 (14%) 6 (86%) 7  
  Grade 2 12 (36%) 21 (64%) 33 0.393
  Grade 3 5 (26%) 14 (74%) 19 0.6465c
  1. IDC invasive ductal carcinoma, TMA tissue microarray, FRA folate receptor alpha, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor type 2, TNM tumor node metastasis.
  2. a P values calculated via 2X2 contingency table analysis using Fisher’s exact test.
  3. b 4/8 (50%) of N1/N2 samples were Her2(+).
  4. c Grade 1 vs Grade 3.